ADCs with ImmunoGen technology are a type of targeted anticancer therapy.
Each ADC contains a highly potent cancer-killing agent attached to an antibody that binds to a target found on tumor cells. The antibody serves to target the potent cancer-killing agent to tumor cells, which the agent can then kill.
ImmunoGen or Partner
Antibody that binds to a target found on tumor cells
Linker, which impacts ADC performance
Highly potent cancer-killing agent
An ADC integrated system
Cancers differ in the targets present on the tumor cells. Scientists can develop ADC compounds for different types of cancers by identifying a suitable target, creating a quality antibody and attaching an effective cancer-killing agent using an appropriate linker.
Last updated: February 10, 2016